Sue Caleo-Naeyaert, Global Head Government Affairs, Policy and Pharmaceconomics at Fresenius Kabi SwissBioSim
Fresenius Kabi SwissBioSim Logo

Sue Caleo-Naeyaert


Global Head Government Affairs, Policy and Pharmaceconomics
Fresenius Kabi SwissBioSim
Biosimilars Commercialisation Summit Agenda 2019

Biosimilars Commercialisation Summit Agenda 2019

View Content

Conference Day Two

Thursday, March 5th, 2020


2:20 PM Patients and the Challenge of Switching

  • Consider how a patient may feel powerless when being forced/ encouraged to switch to a biosimilar 
  • Discuss how the science behind a biosimilar, with respect to complexity, may add to patients skepticism and the importance to educate patients about their safety and efficacy to allay their fears 
  • Explore the commercial significance of switching, with respect to the necessity to switch established patients between brands to allow hospitals to avoid only using biosimilars for new treatment starts 



3:25 PM Panel Discussion: The Market Value of Real World Evidence in the Education of Stakeholders

  • Explore the contentious idea that real world evidence is an unnecessary undertaking in the commercialisation of biosimilars
  • Consider the pros and cons of incremental registration for multiple indications
  • Hear the views of a sponsoring company, pharmacist, and payer

Check out the incredible speaker line-up to see who will be joining Sue.

Download The Latest Agenda